Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative factors: declining margins, increased tax expenses, and unresolved issues with Dr. Tobias on Amazon. Although MusclePharm shows growth, it's primarily from existing customers. Rising protein costs and potential further margin declines are concerning. Despite optimistic guidance for Irwin's online sales, the lack of clarity on subscriber trends and management's avoidance of detailed responses contribute to a negative sentiment. Without a market cap, the negative impact is assumed to be moderate.
Total Revenue $23.5 million, a 47% increase year-over-year. The increase was primarily driven by $6.8 million revenue from the acquisition of Irwin Naturals, with $0.7 million organic growth from other brands. MRC declined, but Legacy FitLife (excluding MRC) delivered 8% organic growth, and MusclePharm delivered 55% organic growth.
Wholesale Revenue $13.2 million, a 156% increase year-over-year. Excluding $6.5 million from Irwin, wholesale revenue for other brands increased 30%, with Legacy FitLife and MusclePharm increasing 4% and 112%, respectively.
Online Revenue $10.3 million, a 5% decrease year-over-year. MRC online revenue declined 16%, Legacy FitLife online revenue (excluding MRC) increased 14%, and MusclePharm online revenue declined 3%.
Gross Margin 37.2%, down from 43.8% in the prior year. Excluding the amortization of inventory step-up in Irwin, gross margin was 38.9%. The decline was due to lower gross margin in MusclePharm and the addition of Irwin, which historically has lower gross margins.
Net Income $0.9 million, down from $2.1 million in the prior year. The decline was due to elevated merger and acquisition-related expenses from the Irwin acquisition, lower gross margin, and higher income tax expense.
Legacy FitLife Revenue $12.9 million, with 68% from online sales and 32% from wholesale customers. This represents a 4% increase in wholesale revenue and an 8% decrease in online revenue, resulting in a 5% total revenue decrease year-over-year. Excluding MRC, online revenue for other Legacy FitLife brands increased 14%.
MusclePharm Revenue Increased 55%, with wholesale revenue up 112% and online revenue down 3%. Gross margin declined to 19.8% due to lower margins in wholesale revenue and rising whey protein costs.
Irwin Naturals Revenue $6.8 million for the 7.5 weeks post-acquisition, with 95% from wholesale customers and 5% from online sales. Gross margin was 32.2%, or 37.9% excluding inventory step-up amortization. Historical gross margins for Irwin have been improving over time.
Irwin Naturals acquisition: FitLife acquired Irwin Naturals on August 8, 2025, contributing $6.8 million in revenue for the 53-day period from August 9 to September 30. The acquisition is expected to enhance online sales and optimize supply chain and fulfillment.
Revenue growth: Total revenue increased 47% year-over-year to $23.5 million in Q3 2025, driven by the Irwin Naturals acquisition and organic growth in other brands.
Wholesale revenue: Wholesale revenue increased 156% year-over-year to $13.2 million, with Irwin contributing $6.5 million. Excluding Irwin, wholesale revenue grew 30%.
Gross margin: Gross margin declined to 37.2% in Q3 2025 from 43.8% in Q3 2024, impacted by lower margins in MusclePharm and the addition of Irwin Naturals.
Online sales: Online revenue decreased 5% year-over-year to $10.3 million, with declines in MRC and MusclePharm offset by a 14% increase in Legacy FitLife online sales (excluding MRC).
Shift to online sales for Irwin Naturals: Ceased wholesale sales to a third-party Amazon seller to focus on direct online sales, generating $10,000 daily revenue from Amazon as of October 2025.
Price adjustments for MusclePharm: Communicating potential price increases to customers starting January 2026 due to rising whey protein costs.
Gross Margin Decline: Gross margin declined to 37.2% during the third quarter of 2025 compared to 43.8% in the prior year, driven by lower margins in the MusclePharm business and the addition of Irwin Naturals, which has historically generated lower gross margins.
MusclePharm Cost Pressures: The cost of whey protein continues to climb, significantly impacting MusclePharm's gross margin, which declined to 19.8%. The company has absorbed these cost increases instead of passing them on to customers, but further cost increases are anticipated.
Consumer Weakness: Evidence of general consumer weakness emerged in late Q3, with declining Amazon subscriber counts and reduced replenishment orders from wholesale customers. This trend is corroborated by reduced traffic at brick-and-mortar locations and low consumer confidence levels.
Irwin Naturals Transition Challenges: The acquisition of Irwin Naturals led to short-term revenue impacts, including $0.6 million in pulled-forward sales by the previous owner and a $0.3 million revenue loss due to ceasing wholesale sales to a third-party Amazon seller.
Online Revenue Decline: Online revenue decreased by 5% year-over-year in Q3 2025, with MRC online revenue declining 16% and MusclePharm online revenue declining 3%.
Merger and Acquisition Costs: Elevated merger and acquisition-related expenses associated with the Irwin Naturals acquisition contributed to a decline in net income for Q3 2025.
Debt and Cash Flow Constraints: The company did not pay down any debt during Q3, using cash flow to cover substantial legal and transaction-related expenses. Debt amortization is set to begin in Q4.
Wholesale Revenue Dependency: Irwin Naturals and MusclePharm have a heavy reliance on wholesale revenue, which typically generates lower margins compared to online sales.
Economic Uncertainty: Broader economic factors, including low consumer confidence and the potential for prolonged consumer weakness, pose risks to revenue stability across all brands and channels.
Whey Protein Costs and Pricing Strategy: The cost of whey protein is expected to continue increasing during the fourth quarter of 2025 and early 2026. The company plans to implement price increases for MusclePharm products effective January 1, 2026, to offset these rising costs.
Irwin Naturals Online Sales Growth: The company expects online sales for Irwin Naturals to grow as it replaces the previous third-party seller on Amazon. Initial sales on Amazon began on October 11, 2025, and are currently generating approximately $10,000 in daily revenue, with further growth anticipated as more product listings become active.
Dr. Tobias Brand Revenue Stability: The company is working to stabilize revenue for the Dr. Tobias brand on Amazon and off-Amazon platforms. Year-over-year comparisons are expected to become easier starting February 2026, potentially leading to greater revenue stability.
Debt Reduction Plans: The company plans to begin reducing its term loan balance starting in the fourth quarter of 2025, following the amortization schedule that begins at the end of December 2025.
Consumer Weakness and Market Trends: The company has observed signs of general consumer weakness, including declining Amazon subscriber counts and reduced replenishment orders from wholesale customers. This trend began in September 2025 and continued into October, with potential risks of persistence or acceleration.
The selected topic was not discussed during the call.
The earnings call reveals several negative factors: declining margins, increased tax expenses, and unresolved issues with Dr. Tobias on Amazon. Although MusclePharm shows growth, it's primarily from existing customers. Rising protein costs and potential further margin declines are concerning. Despite optimistic guidance for Irwin's online sales, the lack of clarity on subscriber trends and management's avoidance of detailed responses contribute to a negative sentiment. Without a market cap, the negative impact is assumed to be moderate.
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
The earnings call highlights several negative aspects: declining revenue and gross profit, reduced margins, significant M&A expenses, and wholesale revenue decline. The Q&A session lacked clarity on MusclePharm's performance and margins, adding uncertainty. Despite some positive aspects like online sales growth and product launches, the weak guidance, declining margins, and absence of a share buyback program suggest a negative market reaction.
The earnings call summary shows strong financial performance with increased gross margin and contribution, and significant revenue growth. Despite a decline in online revenue, wholesale revenue surged, and adjusted EBITDA rose 39% YoY. The Q&A highlighted optimism in rebranding and new products, though management was vague on some details. The lack of new partnerships or guidance changes, and no severe risks identified, points to a positive sentiment. However, uncertainties in promotional expenses and GNC relations slightly temper the outlook, resulting in a positive stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
